ArticleFrontiers in genetics2019
Prognostic Role of
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- TMED family genes and their roles in human diseases.International journal of medical sciences · 2023Pooled it
- Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma.Journal of cellular and molecular medicine · 2023Article
- Trafficking protein TMED3 promotes esophageal squamous cell carcinoma.Biomedical journal · 2023Article
- TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway.Cell & bioscience · 2023Article
- Depleting TMED3 alleviates the development of endometrial carcinoma.Cancer cell international · 2022Article
- TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma.Frontiers in genetics · 2022Article
- TMED3/RPS15A Axis promotes the development and progression of osteosarcoma.Cancer cell international · 2021Article
- TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR.Cell death & disease · 2021Article
- Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells.International journal of oncology · 2021Article
- Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.Journal of biomedical science · 2021Article
- SOCS3 is Related to Cell Proliferation in Neuronal Tissue: An Integrated Analysis of Bioinformatics and Experiments.Frontiers in genetics · 2021Article
- Systemic Multi-Omics Analysis Reveals Amplified P4HA1 Gene Associated With Prognostic and Hypoxic Regulation in Breast Cancer.Frontiers in genetics · 2021Article
- Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2021Article
- FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.International journal of medical sciences · 2020Article
- TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling.OncoTargets and therapy · 2020Article
- Transmembrane emp24 domain proteins in development and disease.Genetics research · 2019Review
- Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer.BioMed research international · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Transmembrane p24 trafficking protein 3 (TMED3) is a metastatic suppressor in colon cancer and hepatocellular carcinoma. However, its function in the progression of clear cell renal cell carcinoma (ccRCC) is unknown. Here, we report that TMED3 could be a new prognostic marker for ccRCC. Patient data were extracted from cohorts in the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Differential expression of TMED3 was observed between the low stage (Stage I and II) and high stage (Stage III and IV) patients in the TCGA and ICGC cohorts and between the low grade (Grade I and II) and high grade (Grade III and IV) patients in the TCGA cohort. Further, we evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.